nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Clinical Trial of the Intradermal TLR2 Agonist CADI-05 for BCG Recurrent and Unresponsive Non-Muscle Invasive Bladder Cancer
|
O’Donnell, Michael A. |
|
2019 |
|
2 |
p. 171-180 |
artikel |
2 |
Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy
|
Hamilton, Zach |
|
2015 |
|
2 |
p. 137-142 |
artikel |
3 |
A Management Algorithm for Mitomycin C Induced Cystitis
|
Luckenbaugh, Amy N. |
|
2017 |
|
2 |
p. 133-138 |
artikel |
4 |
A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy
|
Osawa, Takahiro |
|
2016 |
|
2 |
p. 251-261 |
artikel |
5 |
A New Functional Gene, Zinc Finger Protein 485 (ZNF485), is Involved in Bladder Cancer Proliferation
|
Tan, Yiao |
|
|
|
2 |
p. 165-177 |
artikel |
6 |
A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma
|
Knapp, Deborah W. |
|
2016 |
|
2 |
p. 241-250 |
artikel |
7 |
A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma
|
Shimizu, Nobuaki |
|
|
|
2 |
p. 179-192 |
artikel |
8 |
Arsenic Induced Bladder Cancer
|
Messing, Edward M. |
|
|
|
2 |
p. 223-224 |
artikel |
9 |
Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study
|
Ho, Chung-Han |
|
|
|
2 |
p. 129-138 |
artikel |
10 |
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy
|
Paré, Jean-Françcois |
|
|
|
2 |
p. 175-186 |
artikel |
11 |
Asymptomatic Microscopic Haematuria and Significant Urinary Tract Disease
|
Bryan, Richard T. |
|
2019 |
|
2 |
p. 115-117 |
artikel |
12 |
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection
|
Veskimae, Erik |
|
|
|
2 |
p. 221-241 |
artikel |
13 |
Author Index Volume 1 (2015)
|
|
|
2015 |
|
2 |
p. 189-190 |
artikel |
14 |
Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
|
Steinberg, Ryan L. |
|
2015 |
|
2 |
p. 105-116 |
artikel |
15 |
Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
|
Steinberg, Ryan L. |
|
2016 |
|
2 |
p. 215-224 |
artikel |
16 |
Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly –An International Multicenter Study
|
Schuettfort, Victor M. |
|
|
|
2 |
p. 173-185 |
artikel |
17 |
Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy
|
Boström, Peter J. |
|
2016 |
|
2 |
p. 263-272 |
artikel |
18 |
Bladder Cancer Following Medicaid Expansion: No Changes in the Diagnosis of Muscle-Invasive Disease and Time to Treatment
|
Ko, Oliver S. |
|
|
|
2 |
p. 143-150 |
artikel |
19 |
Bladder Cancer Genetic Susceptibility. A Systematic Review
|
de Maturana, Evangelina López |
|
2018 |
|
2 |
p. 215-226 |
artikel |
20 |
Bladder Cancer Patient Advocacy: A Global Perspective
|
Quale, Diane Zipursky |
|
2015 |
|
2 |
p. 117-122 |
artikel |
21 |
Bladder Preservation for Muscle Invasive Bladder Cancer
|
Mirza, Arafat |
|
2016 |
|
2 |
p. 151-163 |
artikel |
22 |
CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis
|
Masson-Lecomte, Alexandra |
|
2019 |
|
2 |
p. 159-169 |
artikel |
23 |
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
|
Pan, Qi |
|
2017 |
|
2 |
p. 79-88 |
artikel |
24 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S. |
|
2018 |
|
2 |
p. 239-242 |
artikel |
25 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S. |
|
2017 |
|
2 |
p. 139-140 |
artikel |
26 |
Challenging Cases in Urothelial Cancer
|
Soloway, Mark S. |
|
2019 |
|
2 |
p. 181-183 |
artikel |
27 |
Challenging Cases in Urothelial Cancer1
|
Soloway, Mark S. |
|
|
|
2 |
p. 215-217 |
artikel |
28 |
Challenging Cases in Urothelial Cancer: Case 20
|
Soloway, Mark S. |
|
|
|
2 |
p. 253-255 |
artikel |
29 |
Challenging Cases in Urothelial Cancer: Case 24
|
Soloway, Mark S. |
|
|
|
2 |
p. 229-232 |
artikel |
30 |
Challenging Cases in Urothelial Cancer: Case 28: Lynch Syndrome
|
Soloway, Mark S. |
|
|
|
2 |
p. 193-199 |
artikel |
31 |
Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer
|
Ibrahim, Tony |
|
2019 |
|
2 |
p. 87-102 |
artikel |
32 |
Clinical Trials Corner
|
|
|
2016 |
|
2 |
p. 279-282 |
artikel |
33 |
Clinical Trials Corner
|
Agarwal, Piyush K. |
|
2017 |
|
2 |
p. 141-142 |
artikel |
34 |
Clinical Trials Corner
|
|
|
2015 |
|
2 |
p. 181-183 |
artikel |
35 |
Clinical Trials Corner
|
Agarwal, Piyush K. |
|
2018 |
|
2 |
p. 243-244 |
artikel |
36 |
Clinical Trials Corner
|
Agarwal, Piyush K. |
|
2019 |
|
2 |
p. 185-187 |
artikel |
37 |
Clinical Trials Corner
|
Agarwal, Piyush K. |
|
|
|
2 |
p. 219-221 |
artikel |
38 |
Clinical Trials Corner Issue 7(2)
|
Agarwal, Piyush K. |
|
|
|
2 |
p. 257-260 |
artikel |
39 |
Clinical Trials Corner Issue 8(2)
|
Agarwal, Piyush K. |
|
|
|
2 |
p. 233-235 |
artikel |
40 |
Clinical Trials Corner Issue 9(2)
|
Agarwal, Piyush K. |
|
|
|
2 |
p. 187-190 |
artikel |
41 |
Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank
|
Kamat, Ashish M. |
|
2016 |
|
2 |
p. 203-213 |
artikel |
42 |
Comorbidity Scores and Machine Learning Methods Can Improve Risk Assessment in Radical Cystectomy for Bladder Cancer
|
Wessels, Frederik |
|
|
|
2 |
p. 155-163 |
artikel |
43 |
Considerations about Non-Metastatic Bladder Cancer Management During the COVID-19 Pandemic
|
Carvalho, Filipe L.F. |
|
|
|
2 |
p. 99-106 |
artikel |
44 |
Detection of Muscle-Invasive Bladder Cancer on Biparametric MRI Using Vesical Imaging-Reporting and Data System and Apparent Diffusion Coefficient Values (VI-RADS/ADC)
|
Sakamoto, Kazumasa |
|
|
|
2 |
p. 161-169 |
artikel |
45 |
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer
|
Jarow, Jonathan |
|
2015 |
|
2 |
p. 133-136 |
artikel |
46 |
Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference
|
Kaye, Deborah R. |
|
2016 |
|
2 |
p. 225-234 |
artikel |
47 |
Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression
|
Godoy, Guilherme |
|
2016 |
|
2 |
p. 127-137 |
artikel |
48 |
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review
|
Lim, Amy H. |
|
|
|
2 |
p. 193-209 |
artikel |
49 |
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer
|
Melgarejo Segura, María Teresa |
|
|
|
2 |
p. 159-166 |
artikel |
50 |
Evaluation of Hematuria in a Large Public Health Care System
|
Ghandour, Rashed |
|
2019 |
|
2 |
p. 119-129 |
artikel |
51 |
Extraperitoneal Antegrade vs Transperitoneal Open Radical Cystectomy: Single Center Experiences with 200 Cases
|
Özkaptan, Orkunt |
|
|
|
2 |
p. 187-194 |
artikel |
52 |
Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer
|
Bastos, Diogo A. |
|
|
|
2 |
p. 171-186 |
artikel |
53 |
Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol
|
Diana, Pietro |
|
|
|
2 |
p. 119-127 |
artikel |
54 |
Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications
|
Alderson, Meera |
|
|
|
2 |
p. 107-122 |
artikel |
55 |
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer
|
Moore, Assaf |
|
|
|
2 |
p. 141-150 |
artikel |
56 |
Id Proteins Contribute to Tumor Development and MetastaticColonization in a Model of Bladder Carcinogenesis
|
Garcia-Cao, Marta |
|
2015 |
|
2 |
p. 159-170 |
artikel |
57 |
Implementing a New Standard of Care
|
Messing, Edward M. |
|
|
|
2 |
p. 237-239 |
artikel |
58 |
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall Survival
|
Kimura, Takahiro |
|
|
|
2 |
p. 205-211 |
artikel |
59 |
In the World of Bladder Tumors: Size Does Matter
|
Loloi, Justin |
|
|
|
2 |
p. 195-200 |
artikel |
60 |
Low Risk of Severe Complications After a Single, Post-Operative Instillation of Intravesical Chemotherapy in Patients with TaG1G2 Urothelial Bladder Carcinoma
|
van Hoogstraten, Lisa M.C. |
|
|
|
2 |
p. 193-203 |
artikel |
61 |
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1
|
Tu, Megan M. |
|
|
|
2 |
p. 131-145 |
artikel |
62 |
MRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation
|
Walker, Alexandra K. |
|
2019 |
|
2 |
p. 147-157 |
artikel |
63 |
Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies
|
Sommer, Breann C. |
|
2018 |
|
2 |
p. 149-159 |
artikel |
64 |
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer
|
Messing, Edward M. |
|
|
|
2 |
p. 191-192 |
artikel |
65 |
Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences
|
Tazeh, Ngii N. |
|
2017 |
|
2 |
p. 89-94 |
artikel |
66 |
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors
|
Wang, Yuanshuo A. |
|
|
|
2 |
p. 125-139 |
artikel |
67 |
Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers
|
Yang, Alexander |
|
|
|
2 |
p. 211-213 |
artikel |
68 |
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer
|
Zhang, JJ H. |
|
|
|
2 |
p. 109-123 |
artikel |
69 |
Novel Simulation Model of Non-Muscle Invasive Bladder Cancer: A Platform for a Virtual Randomized Trial of Conservative Therapy vs. Cystectomy in BCG Refractory Patients
|
Patel, Sanjay |
|
2015 |
|
2 |
p. 143-150 |
artikel |
70 |
Paper Alert
|
Messing, Edward M. |
|
2015 |
|
2 |
p. 185-187 |
artikel |
71 |
Paper Alert
|
Messing, Edward M. |
|
2016 |
|
2 |
p. 283-284 |
artikel |
72 |
Patient-Derived Urothelial Cancer Xenograft Models: A Systematic Review and Future Perspectives
|
Kita, Yuki |
|
|
|
2 |
p. 131-141 |
artikel |
73 |
Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer
|
Bachir, Bassel G. |
|
2017 |
|
2 |
p. 105-112 |
artikel |
74 |
“Picture this”- Patients’ Drawings of Non-Muscle Invasive Bladder Cancer: A Novel Method to Help Understand How Patients Perceive Their Condition
|
Richards, Helen L. |
|
|
|
2 |
p. 149-159 |
artikel |
75 |
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer
|
Alam, Syed M. |
|
|
|
2 |
p. 167-174 |
artikel |
76 |
Preoperative Risk Factors Predicting Postoperative Complications in Radical Cystectomy for Bladder Cancer
|
Niu, Sida |
|
|
|
2 |
p. 151-159 |
artikel |
77 |
Preventing Bladder Recurrences after Nephroureterectomy for Upper Track Urothelial Cancer
|
Messing, Edward M. |
|
2019 |
|
2 |
p. 189-191 |
artikel |
78 |
Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants
|
Ku, Ja Hyeon |
|
2018 |
|
2 |
p. 195-203 |
artikel |
79 |
Psychological Stress and Suicide in Bladder Cancer Patients
|
Messing, Edward M. |
|
2018 |
|
2 |
p. 245-246 |
artikel |
80 |
Pursuing Quality in the Application of Bladder Cancer Quality of Life Research
|
Mohamed, N.E. |
|
2016 |
|
2 |
p. 139-149 |
artikel |
81 |
Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection
|
Noval Rivas, Magali |
|
|
|
2 |
p. 121-131 |
artikel |
82 |
Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States
|
Galsky, Matthew D. |
|
2018 |
|
2 |
p. 227-238 |
artikel |
83 |
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter
|
Kamat, Ashish M. |
|
|
|
2 |
p. 113-117 |
artikel |
84 |
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
|
Boxley, Peter |
|
|
|
2 |
p. 123-129 |
artikel |
85 |
Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate
|
Kokorovic, Andrea |
|
|
|
2 |
p. 243-252 |
artikel |
86 |
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer
|
Meghani, Khyati |
|
|
|
2 |
p. 101-112 |
artikel |
87 |
Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial
|
Enikeev, Dmitry |
|
|
|
2 |
p. 201-210 |
artikel |
88 |
Significance and Mechanisms Analyses of RB1 Mutation in Bladder Cancer Disease Progression and Drug Selection by Bioinformatics Analysis
|
Zhang, Dingguo |
|
|
|
2 |
p. 133-142 |
artikel |
89 |
Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063)
|
Dalbagni, Guido |
|
2017 |
|
2 |
p. 113-119 |
artikel |
90 |
Single Instillation of Hypertonic Saline Immediately Following Transurethral Resection of Bladder Tumor for Recurrence Prevention –A Phase I Study
|
Modai, Jonathan |
|
|
|
2 |
p. 187-192 |
artikel |
91 |
Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma
|
Grivas, Petros |
|
|
|
2 |
p. 143-148 |
artikel |
92 |
Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer
|
Lerner, Seth P. |
|
2016 |
|
2 |
p. 165-202 |
artikel |
93 |
Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
|
Patel, Vaibhav |
|
2017 |
|
2 |
p. 121-132 |
artikel |
94 |
Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines
|
Zuiverloon, Tahlita C.M. |
|
2018 |
|
2 |
p. 169-183 |
artikel |
95 |
Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra
|
Patschan, Oliver |
|
|
|
2 |
p. 213-220 |
artikel |
96 |
The Development of a Video-based Nutrition Education Curriculum for Patients Undergoing Radical Cystectomy
|
Rola, Jenna |
|
|
|
2 |
p. 151-157 |
artikel |
97 |
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis
|
van Hattum, Jons W. |
|
|
|
2 |
p. 211-228 |
artikel |
98 |
The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New Analysis
|
Kamat, Ashish M. |
|
2016 |
|
2 |
p. 273-278 |
artikel |
99 |
The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands
|
van Hoogstraten, Lisa M.C. |
|
|
|
2 |
p. 139-154 |
artikel |
100 |
The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study
|
Kaiser, Jeenan |
|
2018 |
|
2 |
p. 185-194 |
artikel |
101 |
The Prognostic Value of Previous Irradiation on Survival of Bladder Cancer Patients
|
Krughoff, Kevin |
|
2015 |
|
2 |
p. 171-179 |
artikel |
102 |
The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer
|
Lewis, Gary D. |
|
2018 |
|
2 |
p. 205-213 |
artikel |
103 |
The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy
|
Puttmann, Kathleen |
|
2019 |
|
2 |
p. 103-114 |
artikel |
104 |
The Role of Population-Based Observational Research in Bladder Cancer
|
Robinson, Andrew G. |
|
2015 |
|
2 |
p. 123-131 |
artikel |
105 |
Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study
|
Jahnson, Staffan |
|
|
|
2 |
p. 161-171 |
artikel |
106 |
Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention
|
Zareba, Piotr |
|
2018 |
|
2 |
p. 139-147 |
artikel |
107 |
Transversus Abdominis Plane Blockade as Part of a Multimodal Postoperative Analgesia Plan in Patients Undergoing Radical Cystectomy
|
Matulewicz, Richard S. |
|
2018 |
|
2 |
p. 161-167 |
artikel |
108 |
Treatment Decision Making in Patients with Bladder Cancer
|
Berry, Donna L. |
|
2015 |
|
2 |
p. 151-158 |
artikel |
109 |
Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy
|
Luckenbaugh, Amy N. |
|
2016 |
|
2 |
p. 235-240 |
artikel |
110 |
WBC Associates with Readmission Following Cystectomy
|
McIntosh, Andrew G. |
|
2017 |
|
2 |
p. 95-103 |
artikel |